1. New Insights on PPAR Agonists For Cardiovascular Disease

2. Global Estimates of Type 2 Diabetes in the Adult Population

3. Reasons for Death: UKPDS 33 Intensive Rx

4. Glucose Perturbations in Patients With CAD

5. UKPDS 35: Impact of Increasing A1c on Cardiovascular Disease in T2DM

6. UKPDS 33: Blood Glucose and Vascular Risk in Diabetes

7. ACCORD and ADVANCE: Effects of Intensive Glucose Control on CV Disease and Mortality

8. CARDS: Benefit With Atorvastatin in T2DM

9. UKPDS 38: Blood Pressure Reduction and Vascular Risk

10. STENO-2: Effect of Multifactorial Management on Outcomes in Type 2 Diabetes

11. PPAR-a and PPAR-g Agonists: Target Systems

12. Cardiovascular Outcomes Trials With PPAR-a Acting Agents: Fibrates

13. ACCORD Lipid: Effect of Fenofibrate on Lipid Parameters and CV Outcomes

14. Effects of Fibrates on Cardiovascular Events: A Systematic Review and Meta-Analysis

15. Effects of Fibrates on Coronary Events by Cholesterol and TG Level

16. CV Events With PPAR-g Agonists

17. PROactive: Time to Secondary CV Composite Endpoint

18. Pioglitazone and Risk of CVD in T2DM: Meta-Analysis*

19. CHICAGO: Effect of Pioglitazone on Carotid Artery Intima-media Thickness

21. PPAR-g Agonists: Lipoprotein Effects

22. Effect of Pioglitazone on Atheroma Volume vs Other CV Agents

23. Genes Uniquely Regulated by the TZDs

24. Expected Targets for Dual PPAR-a/g Agonists

25. Dual PPAR-a/g Agonists

26. Dual a/g PPAR Agonist: Effect of Muraglitazar on Lipid Parameters

27. Effect of Muraglitazar on Cardiovascular Outcomes

28. GLAD: Effect of Tesaglitazar vs Pioglitazone on Lipid Measures

29. Effect of Tesaglitazar on Serum Creatinine and Glomerular Filtration

30. The Concept of a “Balanced” Dual PPAR-a/g Agonist

31. PPAR-a/g Transactivation Profiles of Rosiglitazone and Pioglitazone

32. Aleglitazar’s Dual PPAR-a/g Transactivation Profile

33. Gene Profile of Dual PPAR-a/g Agonists

34. SYNCHRONY: Effect of Aleglitazar on A1c in T2DM

35. SYNCHRONY: Effect of Aleglitazar on Lipid Measures in T2DM

36. SYNCHRONY: Effect of Aleglitazar on LDL Particle Size and Number in T2DM

37. SYNCHRONY: Cardiovascular Safety

38. SYNCHRONY: Effect of Aleglitazar on Serum Creatinine in T2DM

39. SESTA R: Impact of Supratherapeutic Doses of Aleglitazar on Renal Function in T2DM

40. ALENEPHRO: Objective and Study Design

41. ALENEPHRO: Effect of Aleglitazar on eGFR and SCr in Patients With Renal Impairment

42. ALECARDIO: Aleglitazar in Patients With T2DM and ACS

43. Program Summary